ESH MM 2018 | Mapping the genomic landscape of Waldenström’s Macroglobulinemia
Steven Treon
• 5 Oct 2018
Steven Treon, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, recounts his recent work on the genomic underpinnings of Waldenström’s macroglobulinemia (WM) and how these could inform future therapeutics, at the European School of Hematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France. Dr Treon also discusses how whole genome sequencing and transcriptomics reveal BCL2 targeted therapy as a promising option for WM.
